Lumida
/NMRA
⌘K
Neumora Therapeutics Inc

Neumora Therapeutics Inc

NMRA
$1.04USD↓-8.77%-0.10 today

MARKET CAP

195.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$4

AI Summary

Stalk
Buy NowMedium

NMRA is basing in an early Stage 1 consolidation with price forming higher highs and higher lows above the short-term EMAs, signaling stabilization and a foundation for a trend reversal. Short-term EMAs (9/21) have shifted to support and price is holding above them, offering a favorable pullback entry. The active Higher Highs & Higher Lows pattern indicates demand dominance and a bullish medium-term stance, despite the long-term downtrend persisting.

  • ↑Seven clinical programs including NMRA 511 and Nevacopran address major unmet neurotherapeutic needs.
  • ↑COSTAL 1 top-line data due by year-end 2025, a key valuation catalyst.
  • ↓Q1 2025 net loss widened to $68 M; Q3 2024 opex at $76.6 M intensifies cash burn.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Neumora Therapeutics Inc. (NASDAQ: NMRA) is a biotechnology firm focused on developing transformative therapies aimed at addressing major brain diseases, notably in the fields of depression and Alzheimer's disease agitation. Positioned within the booming neuroscience sector, Neumora is advancing a diverse pipeline of innovative treatments supported by a robust financial foundation. The company aims to introduce novel mechanisms of action to cater to the pressing public health challenge posed by neural disorders that impact millions globally.

Bull says

  • ↑Seven clinical programs including NMRA 511 and Nevacopran address major unmet neurotherapeutic needs.
  • ↑COSTAL 1 top-line data due by year-end 2025, a key valuation catalyst.
  • ↑Cash and equivalents of $217.6 M as of June 2025 provide runway into 2027.
  • ↑High institutional backing (positive 13F ownership) and QS score signal underlying strength.
  • ↑Low volatility profile may appeal to risk-averse investors amid biotech swings.
  • ↑Pipeline expansion into obesity adds diversification beyond CNS treatments.

Bear says

  • ↓Q1 2025 net loss widened to $68 M; Q3 2024 opex at $76.6 M intensifies cash burn.
  • ↓Negative earnings yield (-2.98%) and poor profitability metrics impair valuation.
  • ↓Early trials lacked statistical significance, highlighting high clinical execution risk.
  • ↓Crowded CNS market and established competitors create adoption uncertainty.
  • ↓Weak growth and momentum factors suggest limited stock traction.
  • ↓Negative dividend signal and profitability pressures reduce shareholder appeal.

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 09-03-2026bullish

Transcript signals

Bull points

  • I will just reiterate our confidence in delivering the top line results around the end of the year and the things that we've put in place and the resources to help ensure that that happens.
  • we feel, as Rob has mentioned, very good, you know, about moving our programs into the clinic in the first half of next year.
  • We've been quite encouraged by the safety profile and that's based on the totality of data from both the phase one and the phase two studies to date.

Bear points

  • we conducted a human PET receptor occupancy study with the intent to assess which doses and exposures are resulting in significant receptor occupancy through the entire dosing period.
Read full transcript analysis ›